GlassScriptPhysician profile
Deepa Panjeti-Moore
NPI 1699185439
$53,780.39
in general payments reported to CMS, 2019-2025
47 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.75 · 2021: $977 · 2022: $1,707 · 2023: $19K · 2024: $20K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Honoraria: $15K · Food and Beverage: $7,795 · Consulting Fee: $6,830 · Travel and Lodging: $5,165 · Education: $50.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,431.00 |
| Honoraria | $14,812.50 |
| Food and Beverage | $7,794.96 |
| Consulting Fee | $6,829.86 |
| Travel and Lodging | $5,165.37 |
| Education | $50.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $22,238.27 | 2021-2025 | Valtoco |
| Sk Life Science, INC. | $17,750.33 | 2021-2025 | Xcopri |
| Neuropace, INC. | $7,649.36 | 2022-2025 | |
| Ucb, INC. | $1,303.75 | 2020-2024 | Fintepla, Briviact |
| Livanova USA, INC. | $1,130.24 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $924.79 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $266.93 | 2021-2022 | |
| Lilly USA, LLC | $173.47 | 2022-2024 | Emgality, Reyvow, Amyvid |
| Genentech USA, INC. | $167.33 | 2022-2023 | Ocrevus, Enspryng |
| Pfizer INC. | $157.00 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $141.53 | 2022-2024 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $124.79 | 2023-2024 | Ingrezza, Ongentys |
| Biohaven Pharmaceuticals, INC. | $122.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $121.29 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $115.02 | 2023-2025 | Daybue, Nuplazid |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Panjeti-Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.